Summary
Sebastian Oehm is a scientist-entrepreneur and Co-Founder & CEO of SynX Therapeutics, building a platform that programs non-natural biology to produce scalable, drug-like molecules for hard-to-drug targets and rapid response to emerging biothreats. He holds a PhD in Synthetic Biology from Cambridge and translated academic expertise at the MRC Laboratory of Molecular Biology and Trinity College into a company that merges high-throughput experimental design with practical manufacturing considerations. His career uniquely spans bench research, biosecurity policy and parliamentary staff work, giving him fluency in both technical development and public-facing risk dialogue. As an Adjunct Assistant Professor at the J. Craig Venter Institute he continues to engage on policy and safety for mirror-life research while leading commercial productisation. Known for coordinating international scientific conversations on potential risks of non-natural biology, he combines rigorous science with a commitment to responsible innovation. Exceptional academic foundations (First Class BA, top Abitur score) and interdisciplinary experience underpin his ability to navigate science, policy and business.
8 years of coding experience
Abitur and A-levels, 1.0 with 898/900 points, Abitur and A-levels, 1.0 with 898/900 points at Gymnasium Marianum Meppen
Doctor of Philosophy - PhD, Biological Sciences (Synthetic Biology), Doctor of Philosophy - PhD, Biological Sciences (Synthetic Biology) at University of Cambridge
German, English, French, Latin